CVS Health stock declined 1.4% to $87.60, underperforming the broader market which gained 1.49%. The stock has fallen 4.49% over the past month. The company is expected to report flat EPS of $1.6 for the upcoming quarter with revenue projected at $105.04 billion (up 2.11% YoY). CVS holds a Zacks Rank #3 (Hold) rating...
BrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA...
Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are...
CVS Health closed down 1.17%, underperforming the S&P 500's 0.45% decline. Despite beating the Medical sector over the past month with a 1.64% gain, the company faces flat EPS projections for the upcoming quarter at $1.6, though full-year earnings are expected to grow 18.81%. CVS trades at a Forward P/E of 11.91, below...
CVS Health's Health Services segment demonstrated strong Q2 2026 performance with revenues rising 11.5% to $51.8B and adjusted operating income climbing 10%. Health Care Delivery revenues jumped nearly 23% driven by Oak Street Health, while Pharmacy Services benefited from favorable drug mix and strong new sales of...
CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools...
CVS Health reported strong Q2 2026 results with adjusted EPS of $2.58 (up 42.5% YoY) and revenues of $106.10 billion (up 7.3%), beating consensus estimates. The company raised full-year 2026 guidance for earnings and revenues. However, estimates have trended downward over the past month with a -6.08% consensus shift,...
CVS Health generated $10.6B in YTD operating cash flow and raised its full-year outlook to at least $11.5B, ending Q2 with $2.7B in cash. The company maintains a leverage ratio of 3.5x and expects improvement as it prioritizes balance-sheet strengthening over share buybacks in 2026-2027. Peers Align Technology and...
The iShares U.S. Healthcare Providers ETF (IHF) is a passively managed fund launched in 2006 that tracks the Dow Jones U.S. Select HealthCare Providers Index. With $1.25 billion in assets, a competitive 0.37% expense ratio, and a Zacks ETF Rank of 2 (Buy), it offers diversified exposure to healthcare providers....
CVS Health stock rallied 3.4-3.7% on Tuesday following bullish commentary from Jefferies analyst Brian Tanquilut, who affirmed a buy rating with a $120 price target (28% upside). The analyst highlighted strong management guidance suggesting 2027 EPS of at least $8.44, upcoming share buybacks, and Aetna's successful...
UnitedHealth Group (UNH) emerges as the stronger investment choice compared to CVS Health (CVS), driven by improving results across UnitedHealthcare and Optum divisions, strong operating cash flows, and more attractive valuation. While CVS shows progress with Aetna margin recovery and pharmacy momentum, it faces 2027...
The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual...
The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified...
Two closed-end funds (CEFs) are trading at significant discounts to net asset value due to market concerns about interest rates under new Fed Chair Kevin Warsh's inflation-focused approach. BlackRock Enhanced Equity Dividend Trust (BDJ) offers a 7.8% monthly dividend at a 6.7% discount, while BlackRock Multi-Sector...
The global healthcare services market is projected to grow from USD 8.62 trillion in 2025 to USD 20.10 trillion by 2035, with a CAGR of 8.87%. Growth is driven by rising chronic disease prevalence, aging populations, and digital healthcare adoption including telehealth and AI-enabled care. The U.S. market is expected...
Fluency has issued a retraction notice advising that a previous news release from June 11, 2026, regarding CVS using Fluency to close enterprise AI deployment gaps should be disregarded by journalists and readers.
Autonomize, a healthcare AI company, announced the appointment of three distinguished leaders to its Advisory Board—Dr. Brian Anderson (CEO of Coalition for Health AI), Bill Fandrich (healthcare and financial services executive), and Keith Reynolds (COO of Welldoc)—along with Mike Longacre as Head of Transformation....
Mizuho analyst Ann Hynes raised her CVS Health price target to $115 per share, implying 13% upside from current levels. The article suggests CVS could see even greater upside potential, potentially reaching $150 per share if it achieves a valuation multiple similar to UnitedHealth Group, given its transformation into a...
Morgan Stanley raised UnitedHealth's price target to $453 from $395 and named it a top pick, citing the company's leadership in AI adoption within managed care. The firm believes AI deployment could drive operational improvements, enhance medical loss ratios, and create new revenue opportunities, with potential for...
CVS Health's dividend is sustainable despite the company pausing annual increases. With Q1 2026 operating cash flow of $4.2 billion and expected annual cash flow of at least $9.5 billion, CVS comfortably covers its $3.39 billion projected dividend payout (representing just over 20% of cash flow). The company's 2.89%...
Headlines via Polygon.io. Links open the original publisher.